Glazer Capital LLC’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Glazer Capital LLC’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-600,368	Closed	-$45.2M	–	803
2022 Q2	$45.2M	Buy	+600,368	New	+$26.7M	1.12%	8

Glazer Capital LLC's TPTX Position: Q3 2022 in Review

Glazer Capital LLC sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 600,368 shares — an estimated $45.2M sold.

Glazer Capital LLC first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $45.2M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Glazer Capital LLC reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Glazer Capital LLC sold 600,368 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $45.2M.
Glazer Capital LLC first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Glazer Capital LLC's Turning Point Therapeutics, Inc. Common Stock position peaked at $45.2M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Glazer Capital LLC's 13F filing for Q3 2022, filed 14 Nov 2022.